Trials / Conditions / Fallopian Tube Serous Adenocarcinoma

Fallopian Tube Serous Adenocarcinoma

22 registered clinical trials studyying Fallopian Tube Serous Adenocarcinoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment NCT04919629	Roswell Park Cancer Institute	Phase 2
Recruiting	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr NCT05415709	Ohio State University Comprehensive Cancer Center	EARLY_Phase 1
Active Not Recruiting	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De NCT04498117	CanariaBio Inc.	Phase 3
Terminated	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors NCT03641287	University of Washington	N/A
Terminated	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739	M.D. Anderson Cancer Center	Phase 2
Completed	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, NCT02853318	Roswell Park Cancer Institute	Phase 2
Active Not Recruiting	Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer NCT02345265	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Re NCT02502266	National Cancer Institute (NCI)	Phase 2 / Phase 3
Completed	Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tu NCT02316834	M.D. Anderson Cancer Center	EARLY_Phase 1
Terminated	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713	Mayo Clinic	Phase 2
Active Not Recruiting	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Can NCT02068794	Mayo Clinic	Phase 1 / Phase 2
Completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707	Mayo Clinic	Phase 1
Unknown	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previo NCT00719303	Gynecologic Oncology Group	Phase 3
Completed	Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian NCT01504126	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, NCT00888615	GOG Foundation	Phase 2
Completed	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746	M.D. Anderson Cancer Center	Phase 2
Completed	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851	National Cancer Institute (NCI)	Phase 3
Terminated	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal NCT00899093	Gynecologic Oncology Group	—
Completed	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian NCT00262847	National Cancer Institute (NCI)	Phase 3
Unknown	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745	GOG Foundation	Phase 3